Germany Drug Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Germany Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Transdermal Patches, Infusion Pumps, and More), Route of Administration (Injectable, Inhalational, Transdermal, and More), Application (Diabetes, Oncology, Cardiovascular, and More), and End Users (Hospitals, Ambulatory Surgical Centres, Homecare Settings, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Germany Drug Delivery Devices Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
View Global Report

Compare market size and growth of Germany Drug Delivery Devices Market with other markets in Healthcare Industry

Germany Drug Delivery Devices Market Analysis by Mordor Intelligence

The Germany drug delivery devices market is valued at USD 10.45 billion in 2025 and is forecast to reach USD 15.90 billion by 2030, registering an 8.75% CAGR. Continuous gains stem from the country’s broad statutory insurance coverage, strong manufacturing base in high-value syringes and autoinjectors, and an expanding pipeline of biologics that require precise administration technologies. High diabetes prevalence, a rising cancer burden, and Germany’s well-resourced hospital network keep demand for injectable systems elevated, while rapid shifts toward home-based care and sustainability goals are opening space for connected, reusable formats. EU-wide joint clinical assessments introduced in 2025, domestic fast-track pathways, and real-time digital adherence tools together shorten launch timelines and support uptake of next-generation devices, even as reference-price rules temper premium options. 

Key Report Takeaways

  • By device type, injectable delivery devices led with 43.45% of Germany drug delivery devices market share in 2024; implantable systems are projected to expand at an 10.24% CAGR to 2030. 
  • By route of administration, injectable routes accounted for 49.67% share of the Germany drug delivery devices market size in 2024, while transdermal delivery is advancing at a 10.03% CAGR through 2030. 
  • By application, diabetes captured 30.23% of Germany drug delivery devices market size in 2024; oncology exhibits the fastest growth at a 9.95% CAGR between 2025-2030. 
  • By end-user, hospitals held 42.55% revenue share in 2024, whereas homecare settings are set to grow at an 10.98% CAGR through 2030.

Segment Analysis

By Device Type: Injectable Systems Maintain Leadership as Implants Accelerate

Injectable devices represented 43.45% of all revenues in 2024, cementing their role in the Germany drug delivery devices market size. Sustained demand arises from biologic therapies that dominate new drug approvals and from continuing preference among clinicians for parenteral accuracy. SCHOTT Pharma’s capacity surge in polymer and glass syringes underscores industry confidence. 

Implantable pumps, micro-chips, and bioresorbable depots post the quickest gains at an 10.24% CAGR. Patient-friendly inhalers preserve share amid a high national burden of chronic respiratory illness, while transdermal patches earn incremental adoption for hormone and pain management. Across categories, embedded connectivity features enhance dose logging and feedback loops, lifting adherence and data-driven care pathways within the Germany drug delivery devices market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Route of Administration: Injectable Dominance with Transdermal Upswing

Injectable delivery retained a 49.67% revenue stake in 2024, reflecting clinician trust in intravenous, subcutaneous, and intramuscular routes for vaccines and large-molecule drugs. This proportion anchors the Germany drug delivery devices market share and is bolstered by next-gen autoinjectors that lower activation force and support 2-5 mL volumes. 

Transdermal formats scale fastest at a 10.03% CAGR on the back of microneedle arrays and wirelessly powered acoustic patches that raise payload size limits. Oral mucosal films gain traction for rapid pain relief, while inhaled, ocular, and nasal modalities extend options for targeted local therapy, together enriching clinical toolkits available to practitioners in the Germany drug delivery devices market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Application: Diabetes Commands Revenues while Oncology Propels Future Growth

Diabetes accounted for 30.23% of the Germany drug delivery devices market size in 2024. Closed-loop AID systems that synchronise CGM and pump algorithms are now widely prescribed, with paediatric guidelines highlighting superior time-in-range during exercise scenarios. 

Oncology devices advance at a 9.95% CAGR as micro-robots, nanoparticle shuttles, and on-body injectors aim to chip away at hospital infusion visits. Cardiovascular, respiratory, and CNS segments maintain steady share, whereas infectious-disease applications spur interest in single-use dual-chamber syringes that simplify lyophilised vaccine reconstitution in the Germany drug delivery devices market.

By End-user: Hospitals Reign but Homecare Gains Ground

Hospitals generated 42.55% of 2024 turnover, reflecting concentration of complex oncology and critical-care infusions. Integrated pharmacy automation and staff familiarity with multi-channel pumps reinforce their centrality. 

Yet homecare settings are on a double-digit growth trajectory (10.98% CAGR) as statutory insurers reimburse nurse visits and connected devices for self-administration. Ambulatory surgical centres and specialist clinics fill the gap between inpatient and home use, widening distribution nodes for suppliers active in the Germany drug delivery devices market.

market segment share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

Germany’s advanced hospital density, export-oriented manufacturing, and universal insurance base combine to support a vibrant domestic ecosystem for drug delivery innovation. Nationwide reimbursement rules guarantee broad patient access while price corridors guide cost containment, creating predictable albeit competitive revenue pools. 

Urban Länder such as North-Rhine-Westphalia and Baden-Württemberg house clusters of device engineers, glass manufacturers, and pharma R&D hubs, accelerating prototype-to-pilot cycles. Eastern regions, historically underserved, are seeing targeted federal grants directed at digital-health rollouts and elder-care technology pilots, gradually balancing regional adoption. 

The demographic reality of a median age nearing 47 and an expanding cohort of multimorbid seniors ensures enduring demand for both high-acuity hospital devices and simplified self-care formats. This blend of sophisticated infrastructure and home-centred preferences cements Germany’s role as the reference market for European launches and attracts cross-border investment into the Germany drug delivery devices market.

Competitive Landscape

The Germany drug delivery devices market is moderately fragmented: global pharma groups supply combination products, mid-sized German engineering firms specialise in precision components, and contract manufacturers offer scalable fill-and-finish services. Strategic alliances predominate. Gerresheimer’s tie-up with Aptar Digital Health pairs mechanical expertise with software analytics to deliver integrated oncology support tools. 

SCHOTT Pharma, leveraging decades of glass science, is shifting toward polymer solutions fit for low-temperature biologics while expanding ready-to-use cartridge lines. Vetter invests in fill-finish expansions in Ravensburg and Langenargen to meet surging outsourcing orders for injectables. Start-ups focusing on microneedle and acoustic-patch platforms inject further dynamism. 

Sustainability credentials are fast becoming bid criteria: on-body systems featuring reusable drive units and recyclable disposables align with hospital and insurer green targets. Meanwhile, price-reference caps prompt firms to highlight total-cost-of-care savings through adherence gains and reduced hospitalisations, sharpening competitive narratives across the Germany drug delivery devices market.

Germany Drug Delivery Devices Industry Leaders

  1. Bayer AG

  2. Becton, Dickinson and Company

  3. Gerresheimer AG

  4. Ypsomed Holding AG

  5. Boehringer Ingelheim International GmbH

  6. *Disclaimer: Major Players sorted in no particular order
Germany Drug Delivery Devices Market Concentrations.png
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2025: SCHOTT Pharma introduced a 1.5 ml ready-to-use sterile cartridge in Germany, adding a compact option to its cartriQ line for stable storage of insulin, GLP-1 therapies and hormones.
  • March 2025: Dexcom revealed new integrations allowing its G7 continuous glucose monitor to link directly with Novo Nordisk’s smart insulin pens, NovoPen 6 and NovoPen Echo Plus, bringing real-time glucose data and dosing closer together.
  • January 2025: BioNxt Solutions will transfer its drug-delivery R&D activities to Gen-Plus CRDO in Munich on 1 March 2025, a move aimed at accelerating development milestones.
  • June 2024: Vetter announced it is relocating its Development Services site from Skokie, Illinois, to Des Plaines and expanding manufacturing capacity in Ravensburg and Langenargen, Germany, to meet rising demand for outsourced injectable production.

Table of Contents for Germany Drug Delivery Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Prevalence and Incidence of Chronic and Infectious Diseases
    • 4.2.2 Growing Trend of Home Healthcare and Aging Population
    • 4.2.3 Increasing Investment in Biosimiliar and Biologics Product Innovation and Development
    • 4.2.4 Government Initiatives Supporting Fast Track Approval and Reimbursemnet
    • 4.2.5 Technological Advancement and Digitalization
    • 4.2.6 Expansion of Contract-Manufacturing Hubs
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Requirements and Product Recalls
    • 4.3.2 G-BA Price Regulation Capping Premiums for Innovative Systems
    • 4.3.3 Market Saturation in Conventional systems Coupled with Patient Compliance and Acceptance Issues
    • 4.3.4 Limited Availability of Specialized Microfluidics & Combination-Product Engineering Talent
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory and Technological Outlook
  • 4.6 Porter’s Five Forces Analysis
    • 4.6.1 Bargaining Power of Suppliers
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Threat of New Entrants
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts (Value-USD)

  • 5.1 By Device Type
    • 5.1.1 Injectable Delivery Devices
    • 5.1.2 Inhalation Delivery Devices
    • 5.1.3 Infusion Pumps
    • 5.1.4 Transdermal Patches
    • 5.1.5 Implantable Drug Delivery Systems
    • 5.1.6 Ocular Inserts & Delivery Implants
    • 5.1.7 Nasal & Buccal Delivery Devices
  • 5.2 By Route of Administration
    • 5.2.1 Injectable
    • 5.2.2 Inhalation
    • 5.2.3 Transdermal
    • 5.2.4 Oral Mucosal (Buccal and Sublingual)
    • 5.2.5 Ocular
    • 5.2.6 Nasal
  • 5.3 By Application
    • 5.3.1 Diabetes
    • 5.3.2 Oncology
    • 5.3.3 Cardiovascular
    • 5.3.4 Respiratory
    • 5.3.5 Central Nervous System Disorders
    • 5.3.6 Infectious Diseases
    • 5.3.7 Others
  • 5.4 By End-user
    • 5.4.1 Hospitals
    • 5.4.2 Ambulatory Surgical Centres
    • 5.4.3 Homecare Settings
    • 5.4.4 Clinics and Speciality Centres
    • 5.4.5 Others

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Strategic Moves
  • 6.3 Market Share Analysis
  • 6.4 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
    • 6.4.1 Becton, Dickinson and Company
    • 6.4.2 Gerresheimer AG
    • 6.4.3 Ypsomed Holding AG
    • 6.4.4 Bayer AG
    • 6.4.5 Boehringer Ingelheim International GmbH
    • 6.4.6 Pfizer Inc.
    • 6.4.7 Solventum
    • 6.4.8 Phillips-Medisize LLC
    • 6.4.9 Novartis AG
    • 6.4.10 Owen Mumford Ltd
    • 6.4.11 Novo Nordisk A/S
    • 6.4.12 Medtronic plc
    • 6.4.13 West Pharmaceutical Services Inc.
    • 6.4.14 SCHOTT AG
    • 6.4.15 Haselmeier GmbH
    • 6.4.16 Sanofi S.A.
    • 6.4.17 Terumo Corporation
    • 6.4.18 Teva Pharmaceutical Industries Ltd.
    • 6.4.19 Vetter Pharma-Fertigung GmbH & Co. KG
    • 6.4.20 Nemera La Verpilliere SAS

7. Market Opportunities and Future Outlook

  • 7.1 White-Space and Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Germany Drug Delivery Devices Market Report Scope

As per the scope, drug delivery devices or system are the tools which are used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances in the body. The Germany Drug Delivery Devices Market is segmented By Route of Administration, Application, and End User.

By Device Type Injectable Delivery Devices
Inhalation Delivery Devices
Infusion Pumps
Transdermal Patches
Implantable Drug Delivery Systems
Ocular Inserts & Delivery Implants
Nasal & Buccal Delivery Devices
By Route of Administration Injectable
Inhalation
Transdermal
Oral Mucosal (Buccal and Sublingual)
Ocular
Nasal
By Application Diabetes
Oncology
Cardiovascular
Respiratory
Central Nervous System Disorders
Infectious Diseases
Others
By End-user Hospitals
Ambulatory Surgical Centres
Homecare Settings
Clinics and Speciality Centres
Others
By Device Type
Injectable Delivery Devices
Inhalation Delivery Devices
Infusion Pumps
Transdermal Patches
Implantable Drug Delivery Systems
Ocular Inserts & Delivery Implants
Nasal & Buccal Delivery Devices
By Route of Administration
Injectable
Inhalation
Transdermal
Oral Mucosal (Buccal and Sublingual)
Ocular
Nasal
By Application
Diabetes
Oncology
Cardiovascular
Respiratory
Central Nervous System Disorders
Infectious Diseases
Others
By End-user
Hospitals
Ambulatory Surgical Centres
Homecare Settings
Clinics and Speciality Centres
Others
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

1. What is the current value of the Germany drug delivery devices market?

The market stands at USD 10.45 billion in 2025 and is projected to grow to USD 15.90 billion by 2030.

2. Which device type generates the highest revenue?

Injectable systems lead with a 43.45% share due to their central role in biologics and chronic-disease therapy.

3. How fast is the homecare segment growing?

Home-based use of drug delivery devices is advancing at an 10.98% CAGR through 2030 on the back of demographic ageing and telehealth adoption.

4. Why are transdermal patches gaining popularity?

New microneedle and acoustic-wave technologies boost skin permeation while offering painless, self-administered dosing.

5. What role do German regulations play in device approvals?

The Medical Research Act and EU HTA alignment shorten clinical-trial and reimbursement timelines, although stringent MDR requirements still raise development costs.

6. Which therapeutic area shows the fastest growth?

Oncology devices post a 9.95% CAGR thanks to micro-robotic carriers and on-body injectors aimed at precise tumour targeting

Page last updated on: June 6, 2025

Germany Drug Delivery Devices Market Report Snapshots